Incyte Corporation (INCY) Business Profile

What it does

Incyte is a biopharmaceutical company that discovers, develops and sells medicines for blood disorders, cancer, and inflammatory and autoimmune diseases. Founded in 2001, it is headquartered in Wilmington, Delaware. William J. Meury is its president and chief executive officer.

Its hematology medicines include Jakafi, prescribed in the United States for certain patients with rare blood cancers and graft-versus-host disease, a complication that can follow a stem-cell transplant. Other blood-disorder products include Monjuvi and Niktimvo. In oncology, Incyte sells Pemazyre and Zynyz for specified cancers. Its inflammation and autoimmunity business includes Opzelura, a prescription cream for certain patients with atopic dermatitis or nonsegmental vitiligo.

Doctors prescribe these medicines to eligible patients, while pharmacies, wholesalers and healthcare providers help distribute or administer them. Incyte markets some products itself and works with partners on others. For example, Novartis sells ruxolitinib outside the United States under the name Jakavi.

The company also develops experimental medicines that cannot be marketed for a use until regulators approve them. Its programs include treatments for blood disorders, solid tumors and inflammatory diseases. Incyte acquired Vega Therapeutics, adding latarsibart, a medicine in Phase 3 development for von Willebrand disease, to its pipeline. Jakafi XR, a once-daily formulation of ruxolitinib, was approved and launched in the second quarter of 2026.

How it makes money

Incyte earns revenue principally by selling prescription medicines and collecting royalties on medicines licensed to other companies. It sells Jakafi in the United States through its own specialty sales and commercial team. Novartis has rights to ruxolitinib for blood disorders and cancer outside the United States, where it sells the medicine as Jakavi and pays Incyte royalties. Incyte is also eligible for development and sales milestone payments under that collaboration.

Other products contribute to sales in hematology, oncology and inflammation and autoimmunity. Opzelura is the largest contributor to Incyte’s business outside Jakafi. Niktimvo is co-commercialized, while Incyte holds worldwide rights to develop and commercialize Zynyz. Lilly sells the licensed medicine Olumiant, and Novartis sells Tabrecta; Incyte receives royalties on their commercial sales. Licensing agreements can also generate upfront and milestone payments when specified events occur.

Product revenue is recorded net of estimated rebates, discounts, returns, distribution fees and patient assistance. Wholesalers can also charge back the difference when eligible customers buy at contracted prices below the wholesalers’ purchase price. Sales and royalties can recur as patients use medicines, although the amount varies with demand, coverage, discounts and purchasing patterns.

Incyte reported $1,286.7 million in net income for the year ended December 31, 2025 and $1.67 billion in total revenue for the second quarter of 2026. The quarter’s sales included a $246 million one-time non-cash benefit from the resolution of the Opzelura Medicaid rebate matter. Excluding that benefit, Incyte reported total net sales growth of 17% from the prior-year quarter.

Customers and how it sells

Incyte’s medicines reach patients through different channels depending on the product and market. Jakafi is distributed primarily through specialty pharmacy providers and wholesalers, which deliver it to patients or their pharmacies. Physicians prescribe the medicine, while healthcare payors influence access through coverage, reimbursement and pricing decisions.

Revenue is concentrated among large customers. In fiscal 2025, Customer C represented 21.0% of revenue and Customer D represented 18.0%. Customer A represented 13.0%, Customer E 11.0% and Customer B 9.00%. These labels do not identify the customers by name.

Incyte conducts discovery, clinical development and commercial operations from Wilmington. It also has clinical development and commercial operations in Europe, Japan and Canada. Its rights and distribution arrangements vary by territory: Incyte markets Jakafi itself in the United States, while Novartis sells Jakavi outside the country. Incyte holds an exclusive license to develop and commercialize Iclusig in Europe and selected other countries.

Incyte reported that Opzelura sales outside the United States in the second quarter of 2026 were $43 million. Its international business includes sales for vitiligo, and the company expects to expand Opzelura in Europe if it receives approval for moderate atopic dermatitis.

Suppliers and costs

Incyte uses third-party manufacturers and service providers alongside its own operations. Its manufacturers must produce medicines in sufficient quantities and meet quality standards. Manufacturing facilities are subject to regulatory inspection, and failures to comply can lead to interrupted production, recalls or other regulatory action.

The company’s cost of product revenues includes manufacturing-related costs, personnel dedicated to production, royalties and profit sharing under collaborations, and amortization of licensed intellectual property. Incyte also pays for research, clinical trials and outside services, as well as sales, marketing and administrative operations. It reported that clinical research and outside-services expense increased from 2024 to 2025 as it invested in late-stage programs.

Licenses can require upfront fees, milestone payments and royalties on future product sales. The company’s arrangements include rights obtained from MacroGenics for retifanlimab and a collaboration with Syndax for axatilimab. Incyte reported GAAP research and development expense of $517 million and selling, general and administrative expense of $352 million for the second quarter of 2026. The company expects development costs to vary with the stages of projects, trial activity and regulatory requirements.

Competitive position

Incyte competes with pharmaceutical and biotechnology companies, research institutions and other organizations developing treatments for the same diseases. Competition extends beyond selling approved drugs: companies also compete for research collaborations, personnel and licenses to drug candidates and technology. Some competitors have greater financial resources, larger development and commercial staffs, and more experience in bringing products to market. Specific competing companies are not identified in Incyte’s discussion of competition.

Incyte relies on patents, regulatory protections, product approvals and commercial operations. Its ruxolitinib composition and use patents, including applicable extensions, currently expire in mid and late 2028, respectively. Opzelura is the first and only FDA-approved treatment for repigmentation of vitiligo lesions. Incyte reported that Niktimvo held approximately one third of the third-line-and-later market in the second quarter of 2026.

Our reading: patents and regulatory exclusivity provide meaningful protection for individual medicines, but their duration and scope vary, and Jakafi’s approaching expirations limit their permanence. Our reading: established prescribing and distribution relationships support commercialization, but they do not prevent rivals from developing alternatives or payors from restricting coverage. Incyte also notes that patents can be challenged, invalidated or circumvented.

Growth opportunities

Incyte is seeking to expand sales beyond Jakafi through existing products, new indications and medicines in development. The company expects its core business excluding Jakafi to approach $3.0 billion to $4.0 billion in net sales by 2030. That is a company expectation, not a reported result.

Near-term plans include building adoption of the newly launched Jakafi XR and pursuing a European launch of Opzelura for moderate atopic dermatitis. Incyte also has regulatory reviews underway for povorcitinib in hidradenitis suppurativa, an inflammatory skin disease, and Monjuvi for first-line treatment of diffuse large B-cell lymphoma. The company anticipates approvals and launches through early 2027, subject to regulatory decisions.

The clinical pipeline includes INCA033989 for blood disorders, INCB161734 for pancreatic cancer and INCA33890 for colorectal cancer. Incyte has initiated Phase 3 studies in these programs. It is also studying INCB123667 in ovarian cancer and ruxolitinib cream in hidradenitis suppurativa. The Vega acquisition added latarsibart in Phase 3 development for von Willebrand disease.

Not every program advances. Incyte discontinued development of INCB160058 after concluding that the molecule had not demonstrated the profile needed to become a differentiated therapy. Future product revenue from the remaining candidates depends on trial results, regulatory approvals and commercialization.

Structural risks

• Jakafi dependence and exclusivity: Incyte depends heavily on Jakafi revenue. Its ability to replace revenue lost after the product’s 2028 loss of exclusivity depends on developing and commercializing other products.
• Drug development and approval: Clinical trials can face inconclusive results, slow enrollment, adverse effects, supply shortages or regulatory requests for more information. Incyte may be unsuccessful in discovering, developing or commercializing candidates.
• Pricing and reimbursement: Governments and other payors seek to manage drug costs through discounts, rebates, lower reimbursement or coverage restrictions. These measures can reduce Incyte’s net product revenue or patients’ access to its medicines.
• Manufacturing and safety: Third-party manufacturers must provide sufficient quantities that meet quality standards. Manufacturing failures, newly identified safety problems or product liability claims can lead to recalls, production interruptions or restrictions.
• Intellectual property and competition: Patents may be challenged, invalidated or circumvented, while competing companies may obtain approvals or commercialize alternative treatments. Legal proceedings to defend intellectual property can also be costly.

Bottom line

Our reading

Our reading: Incyte combines recurring medicine sales and partner royalties with a development pipeline intended to broaden the business beyond Jakafi. The central transition is replacing revenue exposed to Jakafi’s approaching loss of exclusivity while funding trials and launches for other products. The company has several paths to pursue, but their contribution depends on clinical, regulatory and commercial outcomes.